THE DEVASTATING IMPACT OF

CARDIAC AMYLOIDOSIS

CARDIAC AMYLOIDOSIS is caused by **MISFOLDED PROTEINS** that build up in the heart and other parts of the body.[1]

ATTR-CM (transthyretin amyloid cardiomyopathy) and **AL** (Immunoglobulin light chain amyloidosis) account for the majority of cardiac amyloidosis cases.[2]

ATTR-CM is:

- **LIFE-**Threatening[3,4]
- **UNDERDIAGNOSED**[3,4]
- Associated with **HEART FAILURE**[3,4]

SYMPTOMS of **HEART FAILURE:**

- **SHORTNESS** of **BREATH**[4,5]
- **SWELLING**[6]

PATIENT PERSPECTIVES FROM A US SURVEY[7]

DIAGNOSIS

for cardiac amyloidosis patients is often a

LONG AND COMPLEX JOURNEY

Almost **70%** of patients **SAID THEIR CONCERNS** about cardiac amyloidosis symptoms were **IGNORED BY OTHER HCPs** prior to diagnosis

MORE THAN HALF reported being **MISDIAGNOSED** with another condition prior to diagnosis

On average, patients reported seeing **4-5** **DOCTORS** for symptoms related to cardiac amyloidosis prior to a diagnosis

The PHYSICAL AND SOCIAL IMPACT on cardiac amyloidosis patients is SIGNIFICANT

76% of patients agreed that due to their cardiac amyloidosis they often had to **PUT THEIR LIFE ON PAUSE** (eg, by avoiding things like):

- **TRAVELING**
- **SWITCHING JOBS**
- **SOCIALIZING**
- **PHYSICAL FITNESS**

Nearly **70%** of patients living with cardiac amyloidosis said they generally **NEVER FEEL WELL**

More than **70%** of patients said cardiac amyloidosis negatively impacts their **ROMANTIC RELATIONSHIPS/INTIMACY** a lot or a great deal

The EMOTIONAL TOLL of cardiac amyloidosis on patients CANNOT BE OVERLOOKED

FRUSTRATED
STRESSED
OVERWHELMED

Common words patients used to **DESCRIBE THEIR FEELINGS** toward living with cardiac amyloidosis

81% of patients reported that **NO ONE UNDERSTANDS** the **NEGATIVE IMPACT** cardiac amyloidosis has on their everyday life

2/3 of patients were either **VERY** or **EXTREMELY CONCERNED** about their current health

Visit **YourHeartsMessage.com** and speak to a cardiologist for more information about ATTR-CM

amyloidosis foundation — **amyloidosis.org**

AMYLOIDOSIS SUPPORT GROUPS, INC. — **amyloidosissupport.org**

Amyloidosis Research Consortium — **arci.org**

1. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. *Cleveland Clinic Journal of Medicine*. 2017;84(12 suppl 3):12-26. doi:10.3949/ccjm.84.s3.02.
2. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*. 2016;133(24):2404-2412. doi:10.1161/circulationaha.116.021612.
3. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification. *Amyloid*. 2016;23(4): 209-213.
4. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. *Circulation*. 2017;135(14):1357-1377.
5. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Current Opinion in Cardiology. 2018:1. doi:10.1097/hco.0000000000000547.
6. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. *Circulation*. 2012;126(10):1286-1300.
7. Pfizer Data on File. Survey Conducted by Harris Poll, 2018.

This survey was conducted online by Harris Poll on behalf of Pfizer from Nov 9-Dec 10, 2018 among 335 US adults aged 18+ who have been diagnosed by a healthcare professional with heart failure or cardiac amyloidosis, including 75 cardiac amyloidosis patients.